Replimune Group, Inc.

REPL

$10.95

+$5.54 (102.40%)

Open

Positive 3-year IGNYTE survival data at ASCO drives REPL premarket surge

Loading chart...

IndexN/A

Market Cap0.92B

Enterprise Value0.61B

Income$-0.25B

Sales$0.00B

EmployeesN/A

P/E-3.24

P/SN/A

P/B4.27

P/C-2.49

EV/EBITDA-2.03

EV/SalesN/A

EPS (ttm)-3.38

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume28.59M

Shs Outstand0.08B

Change102.40%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Today11:00AMSecurities Fraud Investigation Into Replimune Group Inc. (REPL) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm(globenewswire.com)10:09AMReplimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote(benzinga.com)05:40AMReplimune surges after FDA advisers back skin cancer drug(reuters.com)

Yesterday06:15PMReplimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma(globenewswire.com)05:48PMBragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm(globenewswire.com)05:27PMA Food and Drug Administration advisory panel voted 10-3 for Replimune Group's experimental melanoma therapy, after experts raised doubts about whether the company's data and trial design could be trusted to show the drug works(wsj.com)05:10PMUS FDA panel backs Replimune skin cancer drug study data(reuters.com)10:00AMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL(prnewswire.com)

Jul 2908:00PMREPL INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud(globenewswire.com)03:12PMSecurities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm(businesswire.com)03:04PMReplimune Group Inc. (REPL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation(businesswire.com)

Jul 2809:00PMSecurities Fraud Investigation Into Replimune Group Inc. (REPL) Announced -- Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz(gurufocus.com)08:40PMSecurities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz(businesswire.com)06:21PMReplimune Group, Inc. (REPL) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following FDA Briefing Document(globenewswire.com)02:09PMReplimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff(benzinga.com)01:04PMReplimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy(proactiveinvestors.com)09:02AMReplimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy(proactiveinvestors.com)07:47AMUS FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting(reuters.com)

Jul 1511:28AMJohnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)(globenewswire.com)

Jun 3010:09AMReplimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial(seekingalpha.com)

Jun 2908:00AMReplimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update(globenewswire.com)

Jun 2608:00AMReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma(globenewswire.com)

Jun 102:06PMREPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug(zacks.com)

May 3108:00AMReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting(globenewswire.com)

May 3008:00AMReplimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting(globenewswire.com)

May 2909:53PMHow Replimune's drug got a third chance after the White House intervened(wsj.com)08:51AMReplimune to resubmit twice-rejected drug for approval after FDA shakeup(cnbc.com)08:07AMReplimune reaches agreement with US FDA to resubmit melanoma drug application(reuters.com)

Insider Trading

View All

Insider

Type

Price

Value

Date

Sarchi Christopher

Sell

12.0K

$9.24

$111K

Jun 1, 26

Schwendenman Andrew

Award

10.0K

—

Dec 19, 25

Sarchi Christopher

Award

35.0K

—

Dec 19, 25

Hill Emily Luisa

Award

60.0K

—

Dec 19, 25

Xynos Konstantinos

Award

60.0K

—

Dec 19, 25

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

CEO: Sushil PatelEmployees: 465www.replimune.com

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	$4.58M	$4.14M	N/A	$148.00K	$109.00K
Gross Profit	N/A	N/A	N/A	$-4.58M	$-4.14M	N/A	$-148.00K	$-109.00K
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$261.63M	$234.77M	$177.08M	$116.91M	$78.62M	$56.20M	$30.80M	$19.12M
Operating Income	$-261.63M	$-234.77M	$-177.08M	$-121.48M	$-82.76M	$-56.20M	$-30.95M	$-19.23M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-247.30M	$-215.79M	$-174.28M	$-118.04M	$-80.87M	$-52.63M	$-30.83M	$-19.70M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-3.07	$-3.24	$-2.99	$-2.26	$-1.75	$-1.54	$-1.33	$-0.64
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Replimune Group, Inc.

Insider Trading

Discover more

Replimune Group, Inc.

Insider Trading

Discover more